trial · primary record
Atezolizumab
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 613 |
| Primary completion | 2027-01-01 |
| Primary endpoint | Disease-free survival (Phase II) |
| Registry ID | NCT01810913 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:16.157Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01810913
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Atezolizumab · compound